LA COMBINACION DE LATANOPROST Y TIMOLOL EN PROPORCION FIJA ES EFICAZ PARA TRATAR EL GLAUCOMA DE ANGULO ABIERTO
Artículos relacionadosArtículos relacionadosArtículos relacionados
Artículos afines de siicsalud publicados en los últimos 4 meses
ANTIOXIDANTES Y GLAUCOMA
Clinical Ophthalmology 15:2293-2300
Difundido en siicsalud: 20 abr 2022
ALCOHOL, PRESIÓN INTRAOCULAR Y GLAUCOMA DE ÁNGULO ABIERTO
Ophthalmology :1-53
Difundido en siicsalud: 13 may 2022

LA COMBINACION DE LATANOPROST Y TIMOLOL EN PROPORCION FIJA ES EFICAZ PARA TRATAR EL GLAUCOMA DE ANGULO ABIERTO

(especial para SIIC © Derechos reservados)
La formulación en proporción fija de latanoprost, un análogo de las prostaglandinas, y timolol, un bloqueante de los receptores adrenérgicos beta, es eficaz para reducir la presión intraocular en pacientes con glaucoma de ángulo abierto, y presenta la ventaja adicional de la simpleza de su posología (1 gota, 1 vez por día) y buena tolerabilidad.
feldman9.jpg Autor:
Robert M Feldman
Columnista Experto de SIIC
Artículos publicados por Robert M Feldman
Recepción del artículo
22 de Septiembre, 2006
Aprobación
10 de Octubre, 2006
Primera edición
30 de Julio, 2007
Segunda edición, ampliada y corregida
7 de Junio, 2021

Resumen
El glaucoma, la segunda causa más frecuente de amaurosis en todo el mundo, es una enfermedad crónica, incurable. El objetivo principal del tratamiento médico es preservar la visión mediante la reducción de los valores de la presión intraocular (PIO). Actualmente, se utiliza una variedad de agentes que producen hipotensión ocular, pero numerosos pacientes requieren más de un fármaco para lograr la disminución suficiente de la PIO. Esas combinaciones a menudo implican esquemas complejos de administración, con la consiguiente dificultad para su cumplimiento por parte de los pacientes; tales inconvenientes pueden obviarse con el uso de formulaciones combinadas en proporción preestablecida. La solución oftálmica que contiene la combinación en proporción fija (CPF) de latanoprost (una prostaglandina) al 0.005% y timolol (un betabloqueante) al 0.5%, cuya posología es 1 gota, 1 vez por día, combina dos mecanismos de acción para disminuir la PIO. El latanoprost actúa fundamentalemente a través del incremento del flujo de salida uveoescleral, mientras que el timolol reduce la velocidad de producción de humor acuoso por el epitelio ciliar. Algunos ensayos clínicos demostraron que dicha CPF es tan eficaz para disminuir la PIO como el uso paralelo de sus componentes, y que su efecto es equiparable o superior al de otras combinaciones, en proporción fija o no. Además, posee un perfil de seguridad favorable, equivalente al de sus principios activos individuales. Debido a la conveniencia de la administración 1 sola vez al día, la CPF descrita constituye una opción segura y eficaz para los individuos que no pueden lograr el descenso adecuado de la PIO mediante la monoterapia.

Palabras clave
Latanoprost, Timolol, Combinación fija, Glaucoma, Hipertensión ocular


Artículo completo

(castellano)
Extensión:  +/-13.64 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
Glaucoma, the second leading cause of blindness worldwide, is a chronic, incurable disease. The principal aim of medical treatment is to preserve vision through reduction in levels of intraocular pressure (IOP). A variety of ocular hypotensive agents are currently in use, with many patients requiring more than 1 drug to achieve sufficient lowering of IOP. These combinations often entail complex scheduling, with resultant difficulties in patient compliance that may be obviated through the use of fixed combination (FC) formulations. The FC ophthalmic solution containing 0.005% latanoprost, a prostaglandin, and 0.5% timolol, a β-blocker, administered as one drop once-daily, combines two mechanisms of action to reduce IOP. Latanoprost acts principally through increasing uveoscleral outflow, while timolol decreases the rate of production of aqueous humor by the ciliary epithelium. Clinical trials have demonstrated that FC latanoprost/timolol is as effective in lowering IOP as the concomitant use of its two constituents, and is equivalent or superior to other available fixed or unfixed combinations. Moreover, it has a favorable safety profile, equivalent to that of its individual components. Given the convenience of once-daily dosing, this FC formulation provides a safe and effective option for patients who cannot achieve adequate lowering of IOP through monotherapy.

Key words
Latanoprost, Timolol, Fixed-combination, Glaucoma, Ocular hypertension


Full text
(english)
para suscriptores/ assinantes

Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Oftalmología
Relacionadas: Farmacología, Medicina Farmacéutica, Medicina Interna



Comprar este artículo
Extensión: 13.64 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Robert M Feldman, The Hermann Eye Center, TX 77030, 6411 Fannin, 7th Floor, Jones, Houston, EE.UU.
Patrocinio y reconocimiento:
Pfizer Inc. proporcionó el apoyo financiero para la realización de este trabajo.
Bibliografía del artículo
1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 82(11):844-51, 2004.
2. Quigley HA. New paradigms in the mechanisms and management of glaucoma. Eye 19(12):1241-8, 2005.
3. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 90(3):262-7, 2006.
4. European Glaucoma Society: Terminology and guidelines for glaucoma (2nd ed). European Glaucoma Society, Savona, Italy, 2003.
5. Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review. Am J Health Syst Pharm 62(7):691-9, 2005.
6. Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. Drugs Aging 22(1):1-21, 2005.
7. Alm A, Widengård I, Kjellgren D, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 79:12-16, 1995.
8. Bucci MG, and the Italian Latanoprost Study Group. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. J Glaucoma 8:24-30, 1999.
9. Gurwitz JH, Glynn RJ, Monane M, et al. Treatment for glaucoma: adherence by the elderly. Am J Public Health 83(5):711-6, 1993.
10. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 26(3):233-6, 1995.
11. Konstas AG, Maskaleris G, Gratsonidis S, Sardelli C. Compliance and viewpoint of glaucoma patients in Greece. Eye 14 (Pt 5):752-6, 2000.
12. Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci 63:333-8, 1974.
13. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 15(2):132-5, 2004.
14. Feldman RM. An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension. Expert Opin Pharmacother 5(4):909-21, 2004.
15. Brooks AMV, Gillies WE. Ocular ß-blockers in glaucoma management. Clinical pharmacological aspects. Drugs Aging 2(3):208-21, 1992.
16. Perry CM, McGavin JK, Culy CR, Ibbotson T. Latanoprost: an update of its use in glaucoma and ocular hypertension. Drugs Aging 20(8):597-630, 2003.
17. Rulo AH, Greve EL, Hoyng PF. Additive effect of latanoprost, a prostaglandin F2a analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol 78(12):899-902, 1994.
18. Bron AM, Denis P, Nordmann JP, Rouland JF, Sellem E, Johansson M. Additive IOP-reducing effect of latanoprost in patients insufficiently controlled on timolol. Acta Ophthalmol Scand 79(3):289-93, 2001.
19. Basu S, Sjoquist B, Resul B, Stjernschantz JW. Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Prostaglandins Leukot Essent Fatty Acids 50(4):161-8, 1994.
20. Stjernschantz JW. From PGF(2a)-isopropyl ester to latanoprost: a review of the development of Xalatan: The Proctor Lecture. Invest Ophthalmol Vis Sci 42(6):1134-45, 2001.
21. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2a analog, on aqueous humor dynamics in human eyes. Ophthalmology 100(9):1297-304, 1993.
22. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2a analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 111(10):1351-8, 1993.
23. Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol 47(Suppl 1):S53-64, 2002.
24. Dinslage S, Hueber A, Diestelhorst M, Krieglstein G. The influence of Latanoprost 0.005% on aqueous humor flow and outflow facility in glaucoma patients: a double-masked placebo-controlled clinical study. Graefes Arch Clin Exp Ophthalmol 242(8):654-60, 2004.
25. Lindsey JD, Kashiwagi K, Boyle D, Kashiwagi F, Firestein GS, Weinreb RN. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res 15(8):869-75, 1996.
26. Hinz B, Rosch S, Ramer R, Tamm ER, Brune K. Latanoprost induces matrix metalloproteinase-1 expression in human nonpigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanism. FASEB J 19(13):1929-31, 2005.
27. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res 67(2):179-91, 1998.
28. Sagara T, Gaton DD, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN. Topical prostaglandin F2a treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol 117(6):794-801, 1999.
29. Poyer JF, Millar C, Kaufman PL. Prostaglandin F2a effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci 36(12):2461-5, 1995.
30. Yousufzai SYK, Ye Z, Abdel-Latif AA. Prostaglandin F2a and its analogs induce release of endogenous prostaglandins in iris and ciliary muscles isolated from cat and other mammalian species. Exp Eye Res 63(3):305-10, 1996.
31. Yamaji K, Yoshitomi T, Ishikawa H, Usui S. Prostaglandins E1 and E2, but not F2alpha or latanoprost, inhibit monkey ciliary muscle contraction. Curr Eye Res 30(8):661-5, 2005.
32. Ishii K, Tomidokoro A, Nagahara M, et al. Effects of topical latanoprost on optic nerve head circulation in rabbits, monkeys, and humans. Invest Ophthalmol Vis Sci 42(12):2957-63, 2001.
33. Georgopoulos GT, Diestelhorst M, Fisher R, Ruokonen P, Krieglstein GK. The short-term effect of latanoprost on intraocular pressure and pulsatile ocular blood flow. Acta Ophthalmol Scand 80(1):54-8, 2002.
34. Liu CJ, Ko YC, Cheng CY, Chou JC, Hsu WM, Liu JH. Effect of latanoprost 0.005% and brimonidine tartrate 0.2% on pulsatile ocular blood flow in normal tension glaucoma. Br J Ophthalmol 86(11):1236-9, 2002.
35. Sponsel WE, Paris G, Trigo Y, Pena M. Comparative effects of latanoprost (Xalatan) and unoprostone (Rescula) in patients with open-angle glaucoma and suspected glaucoma. Am J Ophthalmol 134(4):552-9, 2002.
36. Januleviciene I, Harris A, Kagemann L, Siesky B, McCranor L. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients. Acta Ophthalmol Scand 82(6):730-7, 2004.
37. Zeitz O, Matthiessen ET, Reuss J, et al. Effects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: a randomized trial comparing bimatoprost and latanoprost with dorzolamide. BMC Ophthalmol 5(1):6, 2005.
38. Larsson LI. Intraocular pressure over 24 hours after single-dose administration of latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study. Acta Ophthalmol Scand 79(6): 567-71, 2001.
39. Rácz P, Ruzsonyi MR, Nagy ZT, Gagyi Z, Bito LZ. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Arch Ophthalmol 114(3):268-73, 1996.
40. Hedner J, Svedmyr N, Lunde H, Mandahl A. The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma. Surv Ophthalmol 41(Suppl 2):S111-5, 1997.
41. Linden C, Nuija E, Alm A. Effects on IOP restoration and blood-aqueous barrier after long-term treatment with latanoprost in open angle glaucoma and ocular hypertension. Br J Ophthalmol 81(5):370-2, 1997.
42. Timoptic [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2002.
43. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure. In the normal eye. Arch Ophthalmol 96(11):2045-8, 1978.
44. Yablonski ME, Zimmerman TJ, Waltman SR, Becker B. A fluorophotometric study of the effect of topical timolol on aqueous humor dynamics. Exp Eye Res 27(12):135-42, 1978.
45. Zimmerman TJ, Harbin R, Pett M, Kaufman HE. Timolol and facility of outflow. Invest Ophthalmol Vis Sci 16(17):623-624, 1977.
46. Sonntag JR, Brindley GO, Shields MB. Effect of timolol therapy on outflow facility. Invest Ophthalmol Vis Sci 17(13):293-6, 1978.
47. Zimmerman TJ, Kaufman HE. Timolol: a ß-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol 95(4):601-4, 1977.
48. Zimmerman TJ, Kaufman HE. Timolol: Dose response and duration of action. Arch Ophthalmol 95(4):605-7, 1977.
49. Amyot M, Blondeau P. Timolol maleate. Pharmacology and review of the literature. Can J Ophthalmol 14(3):208-14, 1979.
50. Kim JW, Smith PH. Timolol-induced bradycardia. Anesth Analg 59:301, 1980.
51. McMahon CD, Shaffer RN, Hoskins HD Jr, Hetherington J Jr. Adverse effects experienced by patients taking timolol. Am J Ophthalmol 88(4):736-8, 1979.
52. Calissendorff B, Sjöquist B, Högberg G, Grunge-Lowerud A. Bioavailability in the human eye of a fixed combination of latanoprost and timolol compared to monotherapy. J Ocul Pharmacol Ther 18(2):127-31, 2002.
53. Sjöquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol 47(Suppl 1):S6-S12, 2002.
54. Korte JM, Kaila T, Saari KM. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefes Arch Clin Exp Ophthalmol 240(6):430-5, 2002.
55. Villumsen J, Alm A. The effect of adding prostaglandin F2 alpha-isopropylester to timolol in patients with open angle glaucoma. Arch Ophthalmol 108(8):1102-5, 1990.
56. Lee PY, Shao H, Camras CB, Podos SM. Additivity of prostaglandin F2alpha-1-isopropyl ester to timolol in glaucoma patients. Ophthalmology 98(7):1079-82, 1991.
57. Higginbotham EJ, Diestelhorst M, Pfeiffer N, Rouland JF, Alm A. The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications. Surv Ophthalmol 47(Suppl 1):S133-40, 2002.
58. Larsson LI. The effect on diurnal intraocular pressure of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension. Acta Ophthalmol Scand 79(2):125-8, 2001.
59. Diestelhorst M, Almegård B. Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol 236(8):577-81, 1998.
60. Pfeiffer N, for the European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefe's Arch Clin Exp Ophthalmol 240(11):893-9, 2002.
61. Higginbotham EJ, Feldman R, Stile SS, Dubiner H, for the Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy. One-year randomized trial. Arch Ophthalmol 120(7):915-22, 2002.
62. Olander K, Zimmerman TJ, Downes N, Schoenfelder J and the Xalacom/Latanoprost Study Group. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension. Clin Ther 26(10):1619-29, 2004.
63. Konstas AG, Boboridis K, Tzetzi D, Kallinderis K, Jenkins JN, Stewart WC. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol 123(7):898-902, 2005.
64. Magacho L, Reis R, Shetty RK, Santos LC, Avila MP. Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication. Ophthalmology 113(3):442-5, 2006.
65. Diestelhorst M, Larsson LI, for the European Latanoprost Fixed Combination Study Group. A 12-week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open-angle glaucoma and ocular hypertension. Br J Ophthalmol 88:199-203, 2004.
66. Diestelhorst M, Larsson LI, and the European-Canadian Latanoprost Fixed Combination Study Group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology 113(1):70-6, 2006.
67. Martínez de la Casa JM, Castillo A, García Feijóo J, Méndez Hernández C, Fernández Vidal A, García Sánchez J. Concomitant administration of travoprost and brinzolamide versus fixed latanoprost/timolol combined therapy: three-month comparison of efficacy and safety. Curr Med Res Opin 20(9):1333-9, 2004.
68. Stewart WC, Stewart JA, Day D, Sharpe ED. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmol Scand 81(3):242-6, 2003.
69. García Sánchez J, Rouland JF, Spiegel D, et al. A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six-month, evaluator-masked, multicentre study in Europe. Br J Ophthalmol 88(7):877-83, 2004.
70. Shin DH, Feldman RM, Sheu WP, and members of the Fixed Combination Latanoprost/Timolol Study Group. Efficacy and safety of fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology 111(2):276-82, 2004.
71. Konstas AG, Kozobolis VP, Lallos N, Christodoulakis E, Stewart JA, Stewart WC. Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%. Eye 18(12):1264-9, 2004.
72. Stewart WC, Stewart JA, Day DG, Sharpe ED, Jenkins JN. Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy. Eye 18(10):990-5, 2004.
73. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E, for the Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: The early manifest glaucoma trial. Arch Ophthalmol 121(1):48-56, 2003.
74. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, for the Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression. Arch Ophthalmol 120:1268-79, 2002.
75. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 102(12):1743-52, 1995.
76. Konstas AG, Nakos E, Tersis I, Lallos NA, Leech JN, Stewart WC. A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Am J Ophthalmol 133(6):753-7, 2002.
77. Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol 122(7):957-65, 2004.
78. Goldberg I, Li XY, Selaru P, Paggiarino D, the Long-Term Latanoprost Safety Study Group. Results of a randomized, 5-year post marketing safety study of latanoprost compared with usual care in patients with open-angle glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 47:E-Abstract 438, 2006.
79. Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 46(7):2444-50, 2005.
80. Grierson I, Jonsson M, Cracknell K. Latanoprost and pigmentation. Jpn J Ophthalmol 48(6):602-12, 2004.
81. Albert DM, Gangnon RE, Zimbric ML, et al. A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients. Arch Ophthalmol 122(11):1680-5, 2004.
82. Arranz Márquez E, Teus MA, Saornil MA, Méndez MC, Gil R. Analysis of irises with a latanoprost-induced change in iris color. Am J Ophthalmol 138(4):625-30, 2004.
83. Cracknell KP, Grierson I, Hogg P, Majekodunmi AA, Watson P, Marmion V. Melanin in the trabecular meshwork is associated with age, POAG but not latanoprost treatment. A masked morphometric study. Exp Eye Res 82(6):986-93, 2006.
84. Konstas AG, Katsimbris JM, Lallos N, Boukaras GP, Jenkins JN, Stewart WC. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology 112(2):262-6, 2005.
85. Parrish RK, Palmberg P, Sheu WP, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 135(5):688-703, 2003.
86. European Medicines Agency. Summary of positive characteristics for DuoTrav, European Public Assessment Report. Available at: http://www.emea.eu.int/humandocs/Humans/EPAR/duotrav/duotrav.htm. Accessed May 17, 2006.
87. Lass JH, Eriksson GL, Osterling L, Simpson CV, for the Latanoprost Corneal Effects Study Group: Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol. A double-masked, randomized, one-year study. Ophthalmology 108(2):264-71, 2001.

 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618